DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination

Vaccine

Volumn 24, Issue 29-30, 2006, Pages 5655-5669

  Castaldello, Arianna ^a   Brocca Cofano, Egidio ^a   Voltan, Rebecca ^a   Triulzi, Chiara ^a   Altavilla, Giuseppe ^a   Laus, Michele ^c   Sparnacci, Katia ^c   Ballestri, Marco ^d   Tondelli, Luisa ^d   Fortini, Cinzia ^b   Gavioli, Riccardo ^b   Ensoli, Barbara ^e   Caputo, Antonella ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d CNR   (Italy)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Biocompatible nanoparticles; Cellular responses; DNA vaccination; HIV 1 tat

Indexed keywords

DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; MACROGOL; NANOPARTICLE; PLASMID DNA; POLY(METHYL METHACRYLATE); POLYMER; TRANSACTIVATOR PROTEIN;

ADSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BIOCOMPATIBILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; DNA STRUCTURE; DRUG DELIVERY SYSTEM; ELECTRICITY; EMULSION; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; MOUSE STRAIN; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; TH1 CELL; VACCINATION;

AIDS VACCINES; ANIMALS; CATIONS; DRUG DELIVERY SYSTEMS; FEMALE; GENE PRODUCTS, TAT; HIV ANTIBODIES; HIV-1; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED BALB C; NANOSTRUCTURES; POLYETHYLENE GLYCOLS; POLYMERS; POLYMETHYL METHACRYLATE; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; VACCINATION; VACCINES, DNA;

EID: 33745284588     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.05.058     Document Type: Article

References (68)

1. Gurunathan S., Wu C.Y., and Seder R.A. DNA vaccines: a key for inducing long-term cellular immunity. Curr Opin Immunol 12 (2000) 442-447
2. Donnelly J.J., Wahren B., and Liu M.A. DNA vaccines: progress and challenges. J Immunol 175 (2005) 633-639
3. Calarota S., Bratt G., Nordlund S., Hinkula J., Leandersson A.C., Sandstrom E., et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351 (1998) 1320-1325
4. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282 (1998) 476-480
5. Chen W.C., and Huang L. Non-viral vector as vaccine carrier. Adv Gen 54 (2005) 315-337
6. Crommelin D.J.A., Daemen T., Scherphof G., Vingerhoeds M.H., Heeremans J.L.M., Kluft C., et al. Liposomes: vehicles for the targeted and controlled delivery of peptides and proteins. J Control Release 46 (1997) 165-175
7. Nugent J., Wan Po L., and Scott E. Design and delivery of non-parental vaccines. J Clin Pharm Ther 23 (1998) 257-285
8. Thierry A.R., Rabinovich P., Peng B., Mahan L.C., Bryant J.L., and Gallo R.C. Characterization of liposome-mediated gene delivery. Expression, stability and pharmacokinetics of plasmid DNA. Gene Ther 4 (1997) 226-237
9. O'Hagan D.T., Singh M., and Ulmer J.B. Microparticles for the delivery of DNA vaccines. Immunol Rev 199 (2004) 191-200
10. Majeti N.V., and Kumar R. Nano and microparticles as controlled drug delivery devices. J Pharm Sci 3 (2000) 234-258
11. Alpar H.O., Papanicolaou I., and Bramwell V.W. Strategies for DNA vaccine delivery. Expert Opin Drug Deliv 2 (2005) 829-842
12. Rihova B. Biocompatibility of biomaterials: hemocompatibility, immunocompatibility and biocompatibility of solid polymeric materials and soluble targetable polymeric carriers. Adv Drug Deliv Rev 21 (1996) 157-176
13. Cui Z., and Mumper R.J. Genetic immunization using nanoparticles engineered from microemulsion precursors. Pharm Res 19 (2002) 939-946
14. Cui Z., and Mumper R.J. Topical immunization using nanoengineered genetic vaccines. J Control Release 81 (2002) 173-184
15. Cui Z., and Mumper R.J. Intranasal administration of plasmid DNA-coated nanoparticles results in enhanced immune responses. J Pharm Pharmacol 54 (2002) 1195-1203
16. Oster C.G., Kim N., Grode L., Barbu-Tudoran L., Schaper A.K., Kaufmann S.H., et al. Cationic microparticles consisting of poly(lactide-co-glycolide) and polyethylenimine as carriers systems for parental DNA vaccination. J Control Release 104 (2005) 359-377
17. Mollenkopf H.J., Dietrich G., Fensterle J., Grode L., Diehl K.D., Knapp B., et al. Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles. Vaccine 22 (2004) 2690-2695
18. Jabbal-Gill I., Lin W., Jenkins P., Jimenez M., Illum L., Davis S.S., et al. Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines. Vaccine 18 (1999) 238-250
19. Men Y., Thomasin C., Merkle H., and Gander B. A single administration of tetanus toxoid in biodegradable microspheres elicit T cell and antibody responses similar or superior to those obtained with aluminium hydroxide. Vaccine 13 (1995) 683-689
20. Anderson J.M., and Shive M.S. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 28 (1997) 5-24
21. Eldridge J.H., Staas J.K., Meulbroek J.A., Tice T.R., and Gilley R.M. Biodegradable and biocompatible poly(d, l-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun 59 (1991) 2978-2986
22. Johansen P., Men Y., Merkle H.P., and Gander B. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur J Pharm Biopharm 50 (2000) 129-146
23. O'Hagan D.T. Recent advances in vaccine adjuvants for systemic and mucosal administration. J Pharm Pharmacol 59 (1998) 1-10
24. O'Hagan D.T. Recent developments in vaccine delivery systems. Curr Drug Targets Infect Disord 1 (2001) 273-286
25. O'Hagan D.T., Jeffery H., and Davis S.S. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine 11 (1993) 965-969
26. O'Hagan D.T., Rahman D., McGee J.P., Jeffery H., Davies M.C., Williams P., et al. Biodegradable microparticles as controlled release antigen delivery systems. Immunology 73 (1991) 239-242
27. Nedrud J.G., and Lamm M.E. Adjuvants and the mucosal immune system. In: Spriggs D.R., and Koff W.C. (Eds). Topics in vaccine adjuvant research (1991), CRC, Boca Raton 51-67
28. Singh M., Chesko J., Kazzaz J., Ugozzoli M., Kan E., Srivastava I., et al. Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not. Pharm Res 21 (2004) 2148-2152
29. Kim J.H., Taluja A., Knutson K., and Han Bae Y. Stability of bovine serum albumin complexed with PEG-poly(l-histidine) diblock copolymer in PLGA microspheres. J Control Release 109 (2005) 86-100
30. O'Hagan D., Singh M., Ugozzoli M., Wild C., Barnett S., Chen M., et al. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J Virol 75 (2001) 9037-9043
31. Xie H., Gursel I., Ivins B.E., Singh M., O'Hagan D.T., Ulmer J.B., et al. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect Immun 73 (2005) 828-833
32. O'Hagan D.T., Singh M., Dong C., Ugozzoli M., Berger K., Glazer E., et al. Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine 23 (2004) 672-680
33. Singh M., Kazzaz J., Ugozzoli M., Chesko J., and O'Hagan D.T. Charged polylactide co-glycolide microparticles as antigen delivery systems. Expert Opin Biol Ther 4 (2004) 483-491
34. Singh M., Kazzaz J., Chesko J., Soenawan E., Ugozzoli M., Giuliani M., et al. Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. J Pharm Sci 93 (2004) 273-282
35. Stieneker F., Kreuter J., and Lower J. High antibody titers in mice with polymethylmethacrylate nanoparticles as adjuvant for HIV vaccines. AIDS 5 (1991) 431-435
36. Caputo A., Gavioli R., and Ensoli B. Recent advances in the development of HIV-1 Tat-based vaccines. Curr HIV Res 2 (2004) 357-376
37. Ferrantelli F., Cafaro A., and Ensoli B. Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. Curr Opin Biotechnol 15 (2004) 543-556
38. Sparnacci K., Tondelli L., and Laus M. Core shell functional nanospheres for oligonucleotide delivery. III. Stealth nanospheres. J Polym Sci, Polym Chem 38 (2000) 3347-3354
39. Rolland A., Gibassier D., Sado P., and Le Verge R. Purification and physicochemical properties of polyacrylic nanoparticles. J Pharm Belg 41 (1986) 94-105
40. Laus M., Sparnacci K., Lelli M., Vannini R., and Tondelli L. Core-shell functional nanospheres for oligonucleotide delivery. II. J Polym Sci A: Polym Chem 38 (2000) 1110-1117
41. Sparnacci K., Laus M., Tondelli L., Bernardi C., Magnani L., Corticelli F., et al. Core-shell microparticles by dispersion polymerization as promising delivery systems for proteins. J Biomater Sci Polym Edn 16 (2005) 1557-1574
42. Okubo M., Yamamoto Y., and Kamei S. Studies on suspension and emulsion. 58. Xps analysis (esca) of the surface-composition of poly(styrene 2-hydroxyethyl methacrylate) microspheres produced by emulsifier-free emulsion polymerization. Colloid Polym Sci 267 (1989) 861-865
43. Arya S.K., Guo C., Joseph S.F., and Wong-Staal F. The trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 229 (1985) 69-73
44. Wright C.M., Felber B.K., Paskalis H., and Pavlakis G.N. Expression and characterization of the trans-activator of HTLV-III/LAV virus. Science 234 (1986) 988-992
45. Caputo A., Sodroski J.G., and Haseltine W.A. Constitutive expression of HIV-1 tat protein in human Jurkat T cells using a BK virus vector. J Acquir Immune Defic Syndr 3 (1990) 372-379
46. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
47. Caputo A., Gavioli R., Altavilla G., Brocca-Cofano E., Boarini C., Betti M., et al. Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat. Vaccine 21 (2003) 1103-1111
48. Ensoli B., Buonaguro L., Barillari G., Fiorelli V., Gendelman R., Morgan R.A., et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 67 (1993) 277-287
49. Chang H.C., Samaniego F., Nair B.C., Buonaguro L., and Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 11 (1997) 1421-1431
50. Fanales-Belasio E., Moretti S., Nappi F., Barillari G., Micheletti F., Cafaro A., et al. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J Immunol 168 (2002) 197-206
51. Ramakrishna L., Anand K.K., Mohankumar K.M., and Ranga U. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization. J Virol 78 (2004) 9174-9189
52. Gavioli R., Gallerani E., Fortini C., Fabris M., Bottoni A., Canella A., et al. HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J Immunol 173 (2004) 3838-3843
53. Caputo A., Brocca-Cofano E., Castaldello A., De Michele R., Altavilla G., Marchisio M., et al. Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application. Vaccine 22 (2004) 2910-2924
54. Sokak R.R., and Rohlf F.J. Estimation and hypothesis testing. In: Sokak R.R., and Rohlf F. (Eds). Biometry: the principles and practice of statistics in biological research. (1981), Freeman, San Francisco 128-135
55. Caselli E., Betti M., Grossi M.P., Balboni P.G., Rossi C., Boarini C., et al. DNA immunization with HIV-1 tat mutated in the transactivation domain induces humoral and cellular immune response against wild-type Tat. J Immunol 162 (1999) 5631-5638
56. Jilek S., Merkle H.P., and Walter E. DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv Drug Deliv Rev 57 (2005) 377-390
57. Gupta R.K., Chang A.C., and Siber G.R. Biodegradable polymer microspheres as vaccine adjuvants and delivery systems. Dev Biol Stand 92 (1998) 63-78
58. Cui Z., Patel J., Tuzova M., Ray P., Phillips R., Woodward J.G., et al. Strong T cell type-1 immune responses to HIV-1 Tat (1-72) protein-coated nanoparticles. Vaccine 22 (2004) 2631-2640
59. Kaur R., Rauthan M., and Vrati S. Immunogenicity of a cationic microparticle-adsorbed plasmid DNA encoding Japanase encephalistis virus envelope protein. Vaccine 22 (2004) 2776-2782
60. Otten G., Schaefer M., Greer C., Calderon-Cacia M., Coit D., Kazzaz J., et al. Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles. J Virol 77 (2003) 6087-6092
61. Denis-Mize K.S., Dupuis M., Singh M., Woo C., Ugozzoli M., O'Hagan D.T., et al. Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. Cell Immunol 225 (2003) 12-20
62. 14C-poly(methylmethacrylate) nanoparticles in experimental tumor models. Pharm Res 18 (2001) 1613-1619
63. Kasturi S.P., Sachaphibulkij K., and Roy K. Covalent conjugation of polyethyleneimine on biodegradable microparticles for delivery of plasmid DNA vaccines. Biomaterials 26 (2005) 6375-6385
64. Kreuter J., and Speiser P.P. New adjvants on a polymethylmethacrylate base. Infect Immunol 13 (1976) 204-210
65. Hinkula J., Svanholm C., Schawartz S., Lundholm P., Brytting M., Engstrom G., et al. Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. J Virol 71 (1997) 5528-5539
66. Hinkula J., Lundholm P., and Wahren B. Nucleic acid vaccination with HIV regulatory genes: a combination of HIV-1 genes in separate plasmids induces strong immune responses. Vaccine 15 (1997) 874-878
67. Tahtinem M., Strengell M., Collings A., Pitkanen J., Kjerrstrom A., Hakkarainen K., et al. DNA vaccination in mice using HIV-1 nef, rev and tat genes in self-replicating pBN-vector. Vaccine 19 (2001) 2039-2047
68. Cafaro A., Titti F., Fracasso C., Maggiorella M.T., Baroncelli S., Caputo A., et al. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine 19 (2001) 2862-2877